oral tirzepatide vs injectable semaglutide and liraglutide for weight loss in patients with overweight or obesity without diabetes: A short-term cost-effectiveness analysis in the United States Oral vs Injectable Tirzepatide for

From the Australian public healthcare perspective, this came at an incremental cost of AU$4.2 billion for SGLT2is and AU$20.2 billion for GLP-1 RAs, with corresponding ICERs of AU$23,717 and AU$100,705 per QALY gained, respectively

Understanding what happens in your body during the first weeks and beyond helps you stay committed to your weight loss journey and recognize when results are progressing as expected

Sirpiglenastat has anticancer effects by directly targeting tumor metabolism and simultaneously inducing a potent antitumor immune response

Since a VBG is readily available, fairly accurate in the setting of DKA and not as painful to attain, our experts recommend VBGs over ABGs in this setting